BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 9713937)

  • 1. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit.
    Isaka M; Yasuda Y; Kozuka S; Miura Y; Taniguchi T; Matano K; Goto N; Tochikubo K
    Vaccine; 1998 Oct; 16(17):1620-6. PubMed ID: 9713937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal or subcutaneous co-administration of recombinant cholera toxin B subunit stimulates only a slight or no level of the specific IgE response in mice to tetanus toxoid.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Miura Y; Matano K; Goto N; Tochikubo K
    Vaccine; 1999 Feb; 17(7-8):944-8. PubMed ID: 10067701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
    Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Mizokami M; Kozuka S; Taniguchi T; Matano K; Maeyama J; Mizuno K; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2001 Jan; 19(11-12):1460-6. PubMed ID: 11163669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
    Isaka M; Komiya T; Takahashi M; Yasuda Y; Taniguchi T; Zhao Y; Matano K; Matsui H; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2004 Aug; 22(23-24):3061-8. PubMed ID: 15297056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of transcutaneous immunization with co-administered antigen and cholera toxin on systemic and mucosal antibody responses in sheep.
    Chen D; Colditz IG; Glenn GM; Tsonis CG
    Vet Immunol Immunopathol; 2002 Jul; 86(3-4):177-82. PubMed ID: 12007883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Wallerström G; Holmgren J
    Vaccine; 2001 May; 19(25-26):3360-8. PubMed ID: 11348699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant.
    Jackson RJ; Fujihashi K; Xu-Amano J; Kiyono H; Elson CO; McGhee JR
    Infect Immun; 1993 Oct; 61(10):4272-9. PubMed ID: 8406816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Infect Immun; 2000 Oct; 68(10):5749-55. PubMed ID: 10992481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant.
    Wu HY; Russell MW
    Vaccine; 1998; 16(2-3):286-92. PubMed ID: 9607044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice.
    Amuguni JH; Lee S; Kerstein KO; Brown DW; Belitsky BR; Herrmann JE; Keusch GT; Sonenshein AL; Tzipori S
    Vaccine; 2011 Jun; 29(29-30):4778-84. PubMed ID: 21565244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
    Price GA; Russell MW; Cornelissen CN
    Infect Immun; 2005 Jul; 73(7):3945-53. PubMed ID: 15972481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid.
    Westerink MA; Smithson SL; Srivastava N; Blonder J; Coeshott C; Rosenthal GJ
    Vaccine; 2001 Dec; 20(5-6):711-23. PubMed ID: 11738734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
    Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
    Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
    Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
    Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.
    Tochikubo K; Isaka M; Yasuda Y; Kozuka S; Matano K; Miura Y; Taniguchi T
    Vaccine; 1998; 16(2-3):150-5. PubMed ID: 9607023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.